Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;41(12):2195-2203.
doi: 10.1007/s00296-021-05016-w. Epub 2021 Oct 8.

Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Marijana Miler  1 , Nora Nikolac Gabaj  2   3 , Ivana Ćelap  2 , Simeon Grazio  4 , Vedran Tomašić  5 , Alen Bišćanin  5 , Joško Mitrović  6 , Lovorka Đerek  7 , Jadranka Morović-Vergles  8 , Nada Vrkić  3 , Mario Štefanović  2   3
Affiliations

Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Marijana Miler et al. Rheumatol Int. 2021 Dec.

Abstract

The hypothesis of the study was that polymorphisms in promoter regions -238 and -308 of TNF-α could be associated with different clinical outcomes in inflammatory bowel diseases (IBD) and immune-mediated rheumatic diseases (IMRD). The aim was to examine the possible association of both polymorphisms with concentration of C-reactive protein (CRP) and fecal calprotectin (fCAL), onset of the remission and development of the ADA in patients on therapy with anti-TNF inhibitors. The prospective study was done in patients with IBD and IMRD on infliximab (IFX) or adalimumab (ADM). Patients were genotyped for TNF-α -238 and -308 polymorphisms. The concentration of CRP, fCAL, IFX or ADM and antibodies to drugs were measured according to manufacturer's instructions and followed-up for 6 or 12 months. Out of all patients (N = 112), number of patients in remission did not differ according to genotypes (for IBD patients P = 0.509 vs 0.223; for IMRD patients P = 0.541 vs 0.132 for TNF-α -238 and -308, respectively). Initial CRP concentration was higher in IBD patients with TNF-α -308 GG than GA/AA genotypes in patients who failed to achieve remission [11.8 (4.4-39.6) vs 3.1 (1.5-6.5), P = 0.033]. In IBD patients with remission, fCAL concentration after at least 6 months of therapy was higher in TNF-α-308 GG than in GA genotype [52 (25-552) vs 20 (20-20) µg/g, P = 0.041]. Our results showed the association of TNF-α -308 GG genotype with a higher concentration of CRP and fecal calprotectin in patients with inflammatory bowel diseases on IFX or ADM therapy. Clinical remission and development of antibodies to anti-TNF drugs were not associated with TNF-α -238 and -308 polymorphisms.

Keywords: Adalimumab; C-reactive protein; Fecal calprotectin; Immune-mediated rheumatic diseases; Inflammatory bowel diseases; Infliximab; TNF-α polymorphisms.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R et al (2014) The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27(1 Suppl):1–10. https://doi.org/10.1177/03946320140270S101 - DOI - PubMed
    1. Kuek A, Hazleman BL, Ostör AJ (2007) Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83(978):251–260. https://doi.org/10.1136/pgmj.2006.052688 - DOI - PubMed - PMC
    1. Roda G, Jharap B, Neeraj N, Colombel JF (2016) Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 7(1):e135. https://doi.org/10.1038/ctg.2015.63 - DOI - PubMed - PMC
    1. Johnson KJ, Sanchez HN, Schoenbrunner N (2019) Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol 38(11):2967–2976. https://doi.org/10.1007/s10067-019-04684-1 - DOI - PubMed
    1. Aguillón JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M (2006) Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211(1–2):75–84. https://doi.org/10.1016/j.imbio.2005.09.005 - DOI - PubMed

LinkOut - more resources